1990—2019 年中国不孕不育患者的疾病负担研究

作者:Liu Chun; Sun Huixin; Ma Yukun; Xu Lin; Zhang Yixin; Lu Meisong*
来源:Chinese Journal of Reproduction and Contraception, 2023, 43(6): 627-631.
DOI:10.3760/cma.j.cn101441-20220921-00408

摘要

Objective To analyze the prevalence and disease burden of male and female infertility in China from 1990 to 2019. Methods The global disease burden database of 2019 was used to analyze the prevalence of male and female infertility and disability adjusted life years (DALY) in China from 1990 to 2019 among the total Chinese male and female population and different age groups. Results In 2019, the number, prevalence, DALY and DALY rate of male infertility in China were 14 577 432, 2 011.18/100 000, 77 983 person years, 1 076/100 000, respectively. The number, prevalence, DALY and DALY rate of female infertility were 37 884 300, 5 431.22/100 000, 197 046 person years, 28.25/100 000, respectively. The prevalence and disease burden of female infertility were higher than those of male infertility. The age group with the highest male prevalence rate and DALY rate were 35-39 and 30-34 years old respectively, the age group with the highest female prevalence rate and DALY rate were 40-44 and 35-39 years old respectively, and the age group with the highest female prevalence rate and DALY rate was 5 years later than the male age group. From 1990 to 2019, the prevalence rate and DALY rate of male and female infertility increased in the first 20 years or so, and decreased in the last 10 years or so. The prevalence rate and DALY rate of male and female infertility in China were significantly higher than those in the whole world and different socio-demographic index (SDI) regions. Conclusion Although the prevalence rate and DALY rate of male and female infertility in China have decreased in recent years, the population base of China is large, and the disease burden of male and female infertility in the world is still large. Active prevention and treatment measures should be taken to reduce the disease burden of male and female infertility. ? 2023 The Author(s).

全文